Could a new film change how you treat severe allergies?
Researchers found that a new sublingual film called Anaphylm™ could transform how people manage severe allergic reactions, including anaphylaxis. This innovative product, developed by Aquestive Therapeutics, is designed for self-administration and aims to provide a non-invasive alternative to traditional epinephrine injections. The company has reported positive results from its recent human factors and pharmacokinetic studies, indicating that the film is easier to use and effective in delivering the medication quickly.
This development is particularly important for individuals with severe allergies, as timely access to epinephrine can be life-saving. The study showed that the median time to open the packaging was reduced from 17 seconds to just 3 seconds, allowing for quicker response times in emergencies. Additionally, the revised instructions resulted in an over 80% reduction in incorrect film placement, which is crucial for ensuring the medication works effectively. Overall, these improvements could enhance the safety and convenience for those at risk of anaphylaxis.
The evidence comes from early-stage studies, including a human factors validation study and a pharmacokinetic study involving healthy volunteers. While the results are promising, they are not yet conclusive, as the product has not received final approval from the FDA. The company plans to resubmit its New Drug Application in the third quarter of 2026, and it continues to seek regulatory approval in other regions, including Canada and Europe.
For those interested in managing allergies more effectively, staying informed about the progress of Anaphylm™ may be beneficial, as it could offer a new, easier way to handle severe allergic reactions in the near future.